Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) tells Proactive their portfolio company PDS Biotechnology Corp and a subsidiary of Merck & Co Inc (NYSE: MRK), MSD are embarking on a new clinical trial collaboration for metastatic head and neck cancer.
NetScientific 'very pleased' to partner up with Merck for head and neck cancer trial
Quick facts: Netscientific PLC
Price: 5.688 GBX
Market Cap: £4.47 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE